Navigation Links
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Date:6/4/2009

ucleosides, and a streamlined administrative staff.

Dr. Worland added, "I want to acknowledge the tremendous effort and commitment of all our Anadys colleagues, especially those whose positions have been impacted by this restructuring. The current status of ANA598, which now demands our focused investment, has been achieved as a result of each of their contributions."

Proposed ANA598 Phase II Trial Design

Anadys is preparing for the first Phase II trial in hepatitis C patients of ANA598 in combination with interferon-alpha and ribavirin (current standard of care, or SOC) and intends to submit a protocol to the U.S. Federal Drug Administration (FDA) containing the proposed trial design in July 2009. If the FDA allows this trial to proceed, Anadys intends to initiate the trial during the third quarter of 2009.

The current protocol design calls for 12 weeks of dosing ANA598 in naive genotype 1 patients in combination with SOC, compared to a control arm that will receive a placebo and SOC. After 12 weeks, patients are expected to continue to receive SOC alone. The primary endpoints of the study are designed to be safety, tolerability and the percentage of patients with undetectable virus at four weeks (defined as Rapid Virologic Response, or RVR) and 12 weeks (defined as Early Virologic Response, or EVR). For patients who achieve an RVR and EVR response, the duration of treatment with SOC after week 12 will be at the clinical investigator's discretion. Anadys expects that some patients who achieve RVR would stop receiving all treatment at 24 weeks. All patients who complete 24 or 48 weeks of treatment will be assessed for virus negativity 12 and 24 weeks after treatment is ended.

The proposed dose levels in this study are 200 mg and 400 mg, each dosed twice daily (bid). In order to maximize early viral suppression, eac
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... Quest Diagnostics Incorporated (NYSE: DGX ), the world,s ... the final results for its previously announced cash tender offer ... (the "Tender Cap") of its 5.125% Senior Notes due 2010 ... The terms and conditions of the tender offer are described ...
... /PRNewswire-FirstCall/ - BioSyntech, Inc. (TSX: BSY), a biotechnology ... announced statistically significant results from an analysis of ... the BST-CarGel(R) randomized clinical trial. Specifically, statistically significant ... BST-CarGel treatment was found during analyses of tissues ...
... for Discovery and Validation of New Biomarker Panels ... Rules-Based Medicine, Incorporated (RBM), the world,s leading multiplexed ... the most comprehensive collection of quantitative immunoassays for ... drug and diagnostic development. The new service, DiscoveryMAP(TM) ...
Cached Biology Technology:Quest Diagnostics Announces Final Tender Offer Results 2Quest Diagnostics Announces Final Tender Offer Results 3BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device 2BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device 3BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device 4BioSyntech Reports Positive Results from Pivotal Trial for BST-CarGel(R) Cartilage Repair Device 5Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 2Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development 3
(Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
(Date:4/17/2014)... fragmentation of forests in the Amazon help create ... to rapid and widespread forest loss during drought ... findings show that forests in the Amazon could ... with forest fires lead to large-scale loss of ... assistant professor of geography, Penn State. , "We ...
(Date:4/17/2014)... have detected new early-warning signs of the potential loss ... far-reaching implications for the diagnosis and treatment of diabetic ... Americans. , "We had not expected to see such ... said Ann Elsner, professor and associate dean in the ... study. "We set out to study the early signs, ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Angeles, Calif., May 22, 2011Some men of African descent may ... to research conducted at the Keck School of Medicine of ... study, published in the journal Nature Genetics on ... in men of African descent, who tend to more susceptible ...
... Researchers from the Centers for Disease Control and ... to prion diseases, looking at hunting, venison consumption, and ... reported in animals. Three prion diseases in particular ... Creutzfeldt-Jakob disease (vCJD), and chronic wasting disease (CWD) ...
... forces that guide how cells migratehow they manage to get ... living body are poorly understood. Scientists at the Harvard School ... Catalonia (IBEC) have, for the first time, devised a way ... conclusion is that the cells fight it out, each pushing ...
Cached Biology News:USC research determines apparent genetic link to prostate cancer in African-American men 2CDC assesses potential human exposure to prion diseases 2CDC assesses potential human exposure to prion diseases 3The dance of the cells: A minuet or a mosh? 2The dance of the cells: A minuet or a mosh? 3
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
A431 cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Madin-Darby bovine kidney (MDBK) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
... Mutation Explorer processes up to 48 ... traces. Data input can be from either ... terminator or primer chemistries. The detection parameters ... analyst to analyst consistency. We have ...
Biology Products: